Maury Raycroft
Stock Analyst at Jefferies
(0.56)
# 3,903
Out of 4,855 analysts
47
Total ratings
21.62%
Success rate
-17.55%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Maury Raycroft
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CRBP Corbus Pharmaceuticals Holdings | Maintains: Buy | $70 → $53 | $9.23 | +474.21% | 2 | Mar 11, 2025 | |
| CMPX Compass Therapeutics | Maintains: Buy | $7 → $8 | $2.50 | +220.00% | 2 | Feb 10, 2025 | |
| SGMO Sangamo Therapeutics | Maintains: Buy | $7 → $3 | $0.53 | +466.04% | 1 | Dec 31, 2024 | |
| MREO Mereo BioPharma Group | Initiates: Buy | $7 | $2.74 | +155.47% | 1 | Dec 6, 2024 | |
| ERAS Erasca | Initiates: Buy | $6 | $1.60 | +275.00% | 1 | Nov 18, 2024 | |
| INZY Inozyme Pharma | Assumes: Buy | $16 → $17 | $3.99 | +326.07% | 1 | Aug 13, 2024 | |
| TNGX Tango Therapeutics | Initiates: Buy | $19 | $4.26 | +346.01% | 1 | Jul 17, 2024 | |
| PRME Prime Medicine | Assumes: Buy | $23 → $15 | $1.69 | +787.57% | 1 | May 7, 2024 | |
| DNTH Dianthus Therapeutics | Maintains: Buy | $22 → $39 | $18.85 | +106.95% | 2 | Mar 22, 2024 | |
| CUE Cue Biopharma | Initiates: Buy | $6 | $0.64 | +836.04% | 1 | Mar 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $23 | $1.73 | +1,229.48% | 1 | Mar 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $195 | $8.25 | +2,264.87% | 1 | Feb 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $11 | $11.04 | -0.36% | 8 | Aug 4, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $32 → $6 | $22.70 | -73.57% | 2 | Jan 4, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $92 → $75 | $16.81 | +346.16% | 5 | Nov 29, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $218 → $232 | $300.83 | -22.88% | 1 | Oct 3, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $11 | $4.43 | +148.31% | 1 | Sep 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $31 → $27 | $10.55 | +155.92% | 3 | Mar 8, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $38 → $5 | $1.70 | +194.12% | 2 | Dec 2, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $48 | $13.07 | +267.39% | 1 | Sep 7, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $36 | $6.07 | +493.08% | 1 | Jun 1, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $105 | $4.54 | +2,212.78% | 1 | May 27, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $172 | $41.86 | +310.89% | 2 | Apr 21, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $47 | $2.58 | +1,721.71% | 1 | Feb 24, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $230 | $4.44 | +5,086.02% | 1 | Jul 16, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $36 → $42 | $8.09 | +419.16% | 3 | Nov 1, 2017 |
Corbus Pharmaceuticals Holdings
Mar 11, 2025
Maintains: Buy
Price Target: $70 → $53
Current: $9.23
Upside: +474.21%
Compass Therapeutics
Feb 10, 2025
Maintains: Buy
Price Target: $7 → $8
Current: $2.50
Upside: +220.00%
Sangamo Therapeutics
Dec 31, 2024
Maintains: Buy
Price Target: $7 → $3
Current: $0.53
Upside: +466.04%
Mereo BioPharma Group
Dec 6, 2024
Initiates: Buy
Price Target: $7
Current: $2.74
Upside: +155.47%
Erasca
Nov 18, 2024
Initiates: Buy
Price Target: $6
Current: $1.60
Upside: +275.00%
Inozyme Pharma
Aug 13, 2024
Assumes: Buy
Price Target: $16 → $17
Current: $3.99
Upside: +326.07%
Tango Therapeutics
Jul 17, 2024
Initiates: Buy
Price Target: $19
Current: $4.26
Upside: +346.01%
Prime Medicine
May 7, 2024
Assumes: Buy
Price Target: $23 → $15
Current: $1.69
Upside: +787.57%
Dianthus Therapeutics
Mar 22, 2024
Maintains: Buy
Price Target: $22 → $39
Current: $18.85
Upside: +106.95%
Cue Biopharma
Mar 13, 2024
Initiates: Buy
Price Target: $6
Current: $0.64
Upside: +836.04%
Mar 5, 2024
Initiates: Buy
Price Target: $23
Current: $1.73
Upside: +1,229.48%
Feb 8, 2024
Initiates: Buy
Price Target: $195
Current: $8.25
Upside: +2,264.87%
Aug 4, 2023
Upgrades: Buy
Price Target: $11
Current: $11.04
Upside: -0.36%
Jan 4, 2023
Downgrades: Hold
Price Target: $32 → $6
Current: $22.70
Upside: -73.57%
Nov 29, 2022
Maintains: Buy
Price Target: $92 → $75
Current: $16.81
Upside: +346.16%
Oct 3, 2022
Maintains: Buy
Price Target: $218 → $232
Current: $300.83
Upside: -22.88%
Sep 12, 2022
Initiates: Buy
Price Target: $11
Current: $4.43
Upside: +148.31%
Mar 8, 2022
Upgrades: Buy
Price Target: $31 → $27
Current: $10.55
Upside: +155.92%
Dec 2, 2021
Downgrades: Hold
Price Target: $38 → $5
Current: $1.70
Upside: +194.12%
Sep 7, 2021
Initiates: Buy
Price Target: $48
Current: $13.07
Upside: +267.39%
Jun 1, 2021
Initiates: Buy
Price Target: $36
Current: $6.07
Upside: +493.08%
May 27, 2021
Initiates: Buy
Price Target: $105
Current: $4.54
Upside: +2,212.78%
Apr 21, 2021
Upgrades: Buy
Price Target: $172
Current: $41.86
Upside: +310.89%
Feb 24, 2020
Initiates: Buy
Price Target: $47
Current: $2.58
Upside: +1,721.71%
Jul 16, 2018
Initiates: Buy
Price Target: $230
Current: $4.44
Upside: +5,086.02%
Nov 1, 2017
Maintains: Buy
Price Target: $36 → $42
Current: $8.09
Upside: +419.16%